| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Apr―22 |
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19 |
Darren M. Roberts, Xin Liu, Suzanne L. Parker, Andrew Burke, Jenny Peek, Jane E. Carland, Bridin Murnion, Vincent Seah, Steven C. Wallis, Chandra D. Sumi, Saurabh Pandey, Hergen Buscher, Anthony Byrne, Indy Sandaradura, David Bowen, Simon Holz, Adam G. Stewart, Krispin M. Hajkowicz, Jason A. Roberts |
| 2 |
[GO] |
2024―Nov―20 |
Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study |
Toru Ishibashi, Ryosuke Shimizu, Ryuji Kubota |
| 3 |
[GO] |
2024―Nov―15 |
Pharmacokinetics of Enteral Lormetazepam in Mechanically Ventilated ICU Patients with COVID-19: An Adjunct Sedative Study |
Jos L. M. L. le Noble, Kimberly N. Shudofsky, Norbert Foudraine, Nieko Punt, Paddy K. J. Janssen |
| 4 |
[GO] |
2024―Jun―28 |
Correction to: Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19 |
Tim J. L. Smeets, Abraham J. Valkenburg, Mathieu van der Jagt, Birgit C. P. Koch, Henrik Endeman, Diederik A. M. P. J. Gommers, Sebastian D. T. Sassen, Nicole G. M. Hunfeld |
| 5 |
[GO] |
2023―Apr―25 |
Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19 |
Paweł Piwowarczyk, Marta Szczukocka, Wojciech Cios, Paulina Okuńska, Grzegorz Raszewski, Michał Borys, Paweł Wiczling, Mirosław Czuczwar |
| 6 |
[GO] |
2022―Aug―30 |
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review |
María Patricia Hernández-Mitre, Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas E. Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth, Jason A. Roberts |
| 7 |
[GO] |
2022―Jul―29 |
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy |
Maor Wanounou, Yoseph Caraco, René H. Levy, Meir Bialer, Emilio Perucca |
| 8 |
[GO] |
2022―Jul―23 |
Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients? |
Robert Marcec, Robert Likic |
| 9 |
[GO] |
2022―Apr―10 |
Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19 |
Tim J. L. Smeets, Abraham J. Valkenburg, Mathieu van der Jagt, Birgit C. P. Koch, Henrik Endeman, Diederik A. M. P. J. Gommers, Sebastian D. T. Sassen, Nicole G. M. Hunfeld |
| 10 |
[GO] |
2021―Dec―11 |
Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 |
Elizabeth Leung, Ryan L. Crass, Sarah C. J. Jorgensen, Sumit Raybardhan, Bradley J. Langford, W. Justin Moore, Nathaniel J. Rhodes |
| 11 |
[GO] |
2021―Oct―11 |
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study |
Dirk Jan A. R. Moes, David J. van Westerloo, Sandra M. Arend, Jesse J. Swen, Annick de Vries, Henk-Jan Guchelaar, Simone A. Joosten, Mark G. J. de Boer, Teun van Gelder, Judith van Paassen |
| 12 |
[GO] |
2021―Apr―17 |
Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6” |
Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, Filippo Givone, Martina Fabris, Jessica Biasizzo, Carlo Tascini, Federico Pea |
| 13 |
[GO] |
2021―Apr―17 |
Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6” |
Dario Cattaneo, Mario Corbellino, Valeria Cozzi, Marta Fusi, Cristina Gervasoni |
| 14 |
[GO] |
2021―Mar―30 |
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor |
Rita Humeniuk, Anita Mathias, Brian J. Kirby, Justin D. Lutz, Huyen Cao, Anu Osinusi, Darius Babusis, Danielle Porter, Xuelian Wei, John Ling, Y. Sunila Reddy, Polina German |
| 15 |
[GO] |
2020―Aug―27 |
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 |
Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, Filippo Givone, Martina Fabris, Jessica Biasizzo, Carlo Tascini, Federico Pea |
| 16 |
[GO] |
2020―Jul―28 |
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents |
Markus Zeitlinger, Birgit C. P. Koch, Roger Bruggemann, Pieter De Cock, Timothy Felton, Maya Hites, Jennifer Le, Sonia Luque, Alasdair P. MacGowan, Deborah J. E. Marriott, Anouk E. Muller, Kristina Nadrah, David L. Paterson, Joseph F. Standing, João P. Telles, Michael Wölfl-Duchek, Michael Thy, Jason A. Roberts |
| 17 |
[GO] |
2020―Apr―18 |
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |
Cornelis Smit, Mariska Y. M. Peeters, John N. van den Anker, Catherijne A. J. Knibbe |
|
